The all-stock deal for Coefficient Bio gives its VC backer a 38,513% IRR and marks Anthropic's biggest push into life sciences yet.
$400 million for nine employees and eight months of existence. That's what **Anthropic** paid to acquire **Coefficient Bio**, a stealth biotech startup that, as reported by TechCrunch, had barely finished setting up its operations before landing one of the most eye-popping acquisition multiples in biotech history.
## A Bet on Frontier Science
Coefficient Bio was built by **Samuel Stanton** and **Nathan C. Frey**, both alumni of Genentech's computational drug discovery unit Prescient Design. Frey is no academic footnote — he led a team focused on biological foundation models, holds more than 20 publications in journals including *Science Advances* and *Nature Machine Intelligence*, and won the ICLR Outstanding Paper Award in 2024 for his work on Protein Discovery with Discrete Walk-Jump Sampling.
The startup's platform uses AI to draft pharmaceutical R&D plans, manage clinical regulatory strategies, and surface novel drug candidates — operating under the explicit ambition of building what the company called an "artificial superintelligence for science."
Structured entirely in stock, the deal represents roughly **0.1% dilution** for Anthropic — a rounding error for a company carrying a $380 billion post-money valuation following its February 2026 Series G.
## The VC Return That Breaks the Calculator
The most staggering number here isn't the acquisition price. **Dimension**, the venture firm founded in 2023 by Adam Goulburn, Zavain Dar, and Nan Li, held roughly 50% of Coefficient Bio. According to The Next Web, Dimension recorded an internal rate of return of **38,513%**.
That figure isn't a typo — it reflects a new reality: in deep-tech AI, an eight-month gestation period is now long enough to generate generational venture returns. The math implies that Dimension invested a few million dollars and walked away with roughly $200 million in Anthropic stock.
This is what competitive panic looks like in spreadsheet form, as Newcomer detailed in its reporting on the Dimension-backed deal.
## Anthropic's Life Sciences Playbook
Anthropic isn't stumbling into biotech. **Eric Kauderer-Abrams**, hired in 2025 to lead the company's Healthcare Life Sciences group, has been explicit about the target: "We want a significant percentage of all life sciences work in the world to run on Claude, the same way that coding does today," he told CNBC.
The company launched Claude for Life Sciences in October 2025, with integrations for **Benchling**, **PubMed**, and **10x Genomics** already live.
## Why Buy Instead of Build?
The Coefficient Bio acquisition accelerates that roadmap considerably. Coefficient's founders bring not just credentials but a working platform — something Anthropic could theoretically have built internally but chose to buy instead. Speed apparently matters more than build cost when your annualized revenue is $14 billion and growing 10x per year.
---SOURCES---
- Anthropic buys biotech startup Coefficient Bio in $400M deal — TechCrunch
- Anthropic acquires biotech AI startup Coefficient Bio for $400 million — The Next Web
- Anthropic Buys Stealth Dimension-Backed Coefficient Bio in $400M+ Stock Deal — Newcomer
- Anthropic raises another $30B in Series G, with a new value of $380B — TechCrunch
- Anthropic Targets BioTech Growth With $400 Million Coefficient Bio Buy — PYMNTS
- Claude for Life Sciences — Anthropic
- Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost — CNBC
- ICLR 2024 Outstanding Paper Awards — ICLR Blog
- Protein Discovery with Discrete Walk-Jump Sampling — arXiv